Catalysts for PL Developments Copiague LLC
18 tracked
Apr 14, 2026
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Mar 10, 2026
approval
ADAPALENE — FDA approval
PL Developments Copiague LLC
→
Feb 5, 2026
approval
NICOTINE POLACRILEX — FDA approval
PL Developments Copiague LLC
→
Oct 23, 2025
approval
DOCOSANOL — FDA approval
PL Developments Copiague LLC
→
Oct 3, 2025
approval
DOCOSANOL — FDA approval
PL Developments Copiague LLC
→
Jul 8, 2019
approval
ADAPALENE — FDA approval
PL Developments Copiague LLC
→
Jan 10, 2017
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Apr 30, 2015
approval
NICOTINE POLACRILEX — FDA approval
PL Developments Copiague LLC
→
Jan 30, 2015
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Jan 28, 2013
approval
NICOTINE POLACRILEX — FDA approval
PL Developments Copiague LLC
→
Jun 2, 2010
approval
ADAPALENE — FDA approval
PL Developments Copiague LLC
→
Jul 8, 2009
approval
NICOTINE POLACRILEX — FDA approval
PL Developments Copiague LLC
→
Feb 8, 2008
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
May 23, 2007
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Dec 13, 2002
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Sep 18, 2001
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Mar 12, 2001
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→
Jul 25, 2000
approval
ABREVA (DOCOSANOL) — FDA approval
PL Developments Copiague LLC
→